Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Tolerability

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    14,030 result(s) found for: Tolerability. Displaying page 5 of 702.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2004-005122-45 Sponsor Protocol Number: D1441L00032 Start Date*: 2005-05-18
    Sponsor Name:AstraZeneca GmbH
    Full Title: RACE : Rapid Dose Escalation of Quetiapine versus Conventional Escalation in the Treatment of Patients with Acute Schizophrenia – a Multicentre, Double-blind, Parallel group, Randomized Study
    Medical condition: Patients hospitalised with a DSM-IV diagnosis of schizophrenia showing acute agitation and psychosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004993-40 Sponsor Protocol Number: MK-0431-081 Start Date*: 2015-04-01
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Single-Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Sitagliptin in Adolescents
    Medical condition: Type 2 Diabetes Mellitus
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-002796-23 Sponsor Protocol Number: RHINO-CZ-2015-01 Start Date*: 2015-09-10
    Sponsor Name:Laboratoire de la Mer
    Full Title: Multicenter, parallel, randomized, single-blind trial comparing the efficacy and tolerability of Rhinaction®, an osmotic decongestant nasal spray containing essential oils versus Olynth® 0.1%, a va...
    Medical condition: Acute rhinitis Adults aged ≥18years old suffering from acute rhinitis with symptoms present for up to 72h. The purpose of this study is to demonstrate the efficacy and compare safety and tolerab...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002083-27 Sponsor Protocol Number: KAD169 Start Date*: 2012-10-29
    Sponsor Name:Dr. Kade Pharmazeutische Fabrik GmbH
    Full Title: Placebo-controlled double-blind trial investigating the efficacy and tolerability of Posterisan® akut with lidocaine 60 mg/suppository in abatement of complaints associated with hemorrhoids
    Medical condition: Relief of complaints associated with hemorrhoids (pain, burning, itching)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004865 10002580 Anorectal therapeutic procedures HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-003954-95 Sponsor Protocol Number: E550-PRU-2012 Start Date*: 2012-12-03
    Sponsor Name:Spirig Pharma AG
    Full Title: Prospective, randomized, double-blind, placebo-controlled, clinical trial to explore the anti-pruritic effect, the safety and local tolerability of a topical Sertaconazol cream 2% in patients with ...
    Medical condition: Atopic Dermatitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-006283-42 Sponsor Protocol Number: KAD166 Start Date*: 2012-04-30
    Sponsor Name:Dr. Kade Pharmazeutische Fabrik GmbH
    Full Title: Placebo-controlled double-blind trial investigating the efficacy and tolerability of Posterisan® akut with lidocaine (50 mg/g rectal ointment) in abatement of complaints associated with the anorect...
    Medical condition: Relief of complaints associated with anorectal symptom complex (pain, burning, itching)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10002580 Anorectal therapeutic procedures HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-000944-13 Sponsor Protocol Number: GEN-004-002 Start Date*: 2014-07-30
    Sponsor Name:Genocea Biosciences, Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of GEN-004, a Pneumococcal Protein Subunit Vaccine, on Colonization Following Intran...
    Medical condition: Pneumococcal Nasal Carriage
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004865 10069594 Pneumococcal immunization LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-022803-24 Sponsor Protocol Number: 3104002 Start Date*: 2011-02-25
    Sponsor Name:Orion Corporation Orion Pharma
    Full Title: SAFETY AND TOLERABILITY OF ODM-201 IN PATIENTS WITH CASTRATE RESISTANT PROSTATE CANCER: OPEN, NON-RANDOMISED, UNCONTROLLED, MULTICENTRE, EXTENSION STUDY TO STUDY 3104001
    Medical condition: Progressive castration resistant prostate cancer (MedDRA: hormone-refractory prostate cancer)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed) FI (Completed) CZ (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2021-000865-33 Sponsor Protocol Number: HUA_AFF_PRP_21 Start Date*: 2021-10-05
    Sponsor Name:INSTITUTO DE INVESTIGACIÓN SANITARIA BIOARABA
    Full Title: Randomized, parallel controlled study with routine clinical practice to evaluate the efficacy and tolerability of PRFC ENDORET® in the treatment of frontal fibrosing alopecia
    Medical condition: • Patients diagnosed with fibrosing frontal alopecia (FFA) with an age greater than or equal to 18 years. • Patient not responding to previous treatments for at least 6 months. • Use of effective...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-005440-17 Sponsor Protocol Number: LOX_2015_PILOT Start Date*: 2015-09-17
    Sponsor Name:Private Universität Witten/Herdecke gGmbH
    Full Title: Tolerability and analgesic efficacy of Loxapine in patients with refractory, chemotherapy-induced neuropathic pain
    Medical condition: Chemotherapy-induced neuropathic pain
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-005165-49 Sponsor Protocol Number: PLX-HF-01 Start Date*: 2018-09-24
    Sponsor Name:Pluristem Ltd.
    Full Title: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, Designed to Determine the Efficacy, Safety, and Tolerability of Intramuscular Administration of Allogeneic PLX-PAD Cell...
    Medical condition: Muscle Injury Following Arthroplasty for Hip Fracture
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10028315 Muscle injuries HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (GB - no longer in EU/EEA) DK (Completed) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-002610-14 Sponsor Protocol Number: 79835 Start Date*: 2021-09-08
    Sponsor Name:Aarhus University Hospital, Department of Neurology
    Full Title: Mestinon and Salbutamol Tolerability and Efficacy as therapy for Post-COVID-19 Myopathy - A randomized, placebo-controlled, rater and subject-blinded, 2x2 crossover study.
    Medical condition: Post-COVID-19 Myopathy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10062913 Muscle weakness conditions HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001070-29 Sponsor Protocol Number: CRF005 Start Date*: 2023-05-26
    Sponsor Name:Chelsea and Westminster NHS Foundation Trust
    Full Title: Efficacy, tolerability and acceptability of the single tablet regimen (STR) Biktarvy® by trans people living with HIV (TPLWH)
    Medical condition: Human Immunodeficiency Virus (HIV) infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10020441 Human immunodeficiency virus infection, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-002317-10 Sponsor Protocol Number: SC-31A Start Date*: 2019-04-17
    Sponsor Name:ROXALL Medizin GmbH
    Full Title: Phase II study to assess the tolerability, safety and efficacy of subcutaneous cluster-immunotherapy in patients suffering from house dust mite allergy
    Medical condition: Allergic rhinitis / rhino-conjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    20.0 100000004870 10020419 House dust mite allergy LLT
    21.1 100000004855 10034382 Perennial allergic rhinitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003676-31 Sponsor Protocol Number: ROCK-ALS Start Date*: 2019-12-31
    Sponsor Name:Georg-August-Universität Göttingen
    Full Title: Inhibition of Rho Kinase (ROCK) with Fasudil as disease-modifying treatment for ALS
    Medical condition: Amyotrophic lateral sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005101-21 Sponsor Protocol Number: GR-OG-279239-01 Start Date*: 2014-12-22
    Sponsor Name:Genera Research Ltd
    Full Title: Safety, tolerability, systemic pharmacokinetics and efficacy of a single dose of Osteogrow (rhBMP6 in autologous Whole Blood Coagulum Derived [WBCD] carrier) delivered locally to the fracture site ...
    Medical condition: Distal radius fracture.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10022117 - Injury, poisoning and procedural complications 10048049 Wrist fracture PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HR (Completed)
    Trial results: View results
    EudraCT Number: 2010-022736-37 Sponsor Protocol Number: Z7202L02 Start Date*: 2011-02-09
    Sponsor Name:Zambon S.p.A.
    Full Title: Efficacy, tolerability and safety of Z7202, a once daily Diclofenac Diethylamine (DEA) medicated plaster in comparison with Flector®, a twice daily Diclofenac Hydroxyethylpyrrolidine medicated plas...
    Medical condition: Diagnosis of single localized post-traumatic painful condition
    Disease: Version SOC Term Classification Code Term Level
    14.0 10022117 - Injury, poisoning and procedural complications 10065016 Post-traumatic pain PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2011-000640-24 Sponsor Protocol Number: NP25733 Start Date*: 2011-08-02
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Multi-Center, Randomized, Double-Blind, Multiple Ascending Dose, Placebo-Controlled, Parallel Group 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of the HC...
    Medical condition: Chronic Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022891 - Investigations 10019752 Hepatitis C virus (HCV) LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2018-004409-17 Sponsor Protocol Number: M16-049 Start Date*: 2019-06-24
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: An Open-label Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects with Severe Atopic Dermatitis
    Medical condition: Severe Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10012438 Dermatitis atopic PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: NO (Completed) NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2011-005872-41 Sponsor Protocol Number: QTZ-EC-0004 Start Date*: 2012-04-25
    Sponsor Name:Astellas Pharma Europe Ltd.
    Full Title: QUTENZA versus pregabalin in subjects with peripheral neuropathic pain: an open-label, randomized, multicenter, noninferiority efficacy and tolerability study
    Medical condition: Patients who have a documented diagnosis of probable or definite Peripheral Neuropathic Pain
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004852 10054095 Neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) FI (Completed) AT (Completed) SK (Completed) ES (Completed) BE (Completed) SI (Completed) GB (Completed) DE (Completed) GR (Completed) PT (Completed) IT (Completed) BG (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 01 09:50:23 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA